Nature's Sunshine Products (NASDAQ:NATR - Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, November 7th. Nature's Sunshine Products has set its FY 2024 guidance at EPS.Parties interested in listening to the company's conference call can do so using this link.
Nature's Sunshine Products (NASDAQ:NATR - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.18). The firm had revenue of $110.55 million for the quarter. Nature's Sunshine Products had a return on equity of 9.79% and a net margin of 3.50%.
Nature's Sunshine Products Trading Down 2.5 %
Shares of Nature's Sunshine Products stock traded down $0.33 during trading on Thursday, hitting $12.66. 31,961 shares of the stock were exchanged, compared to its average volume of 52,798. The company has a fifty day moving average price of $13.36 and a 200-day moving average price of $14.99. The stock has a market capitalization of $237.12 million, a price-to-earnings ratio of 15.21 and a beta of 0.87. Nature's Sunshine Products has a 1-year low of $10.81 and a 1-year high of $21.72.
Analysts Set New Price Targets
A number of equities analysts have weighed in on NATR shares. Canaccord Genuity Group started coverage on Nature's Sunshine Products in a research report on Friday, September 13th. They set a "buy" rating and a $18.00 price target on the stock. DA Davidson dropped their price target on Nature's Sunshine Products from $23.00 to $21.00 and set a "buy" rating on the stock in a research note on Monday, August 12th. Canaccord Genuity Group assumed coverage on shares of Nature's Sunshine Products in a research report on Friday, September 13th. They set a "buy" rating and a $18.00 price objective for the company. Finally, StockNews.com raised shares of Nature's Sunshine Products from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, September 10th.
Get Our Latest Report on Nature's Sunshine Products
Insider Buying and Selling at Nature's Sunshine Products
In other news, major shareholder Fosun Pharmaceutical Shanghai sold 3,000 shares of the business's stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $13.39, for a total value of $40,170.00. Following the completion of the sale, the insider now owns 69,347 shares of the company's stock, valued at approximately $928,556.33. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 7,499 shares of company stock valued at $99,802 in the last ninety days. 4.70% of the stock is currently owned by corporate insiders.
Nature's Sunshine Products Company Profile
(
Get Free Report)
Nature's Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.
Featured Stories
Before you consider Nature's Sunshine Products, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nature's Sunshine Products wasn't on the list.
While Nature's Sunshine Products currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
